Harlan Korea Appoints New President - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Harlan Korea Appoints New President

Untitled Document

Kwan Goo Edmond (Ed) Cho, an industry veteran with experience in life sciences and pharmaceuticals, has been selected as the president of Harlan Korea.

As president, Cho will have full profit and loss responsibility and overall accountability for all aspects of the Harlan Contract Research Services (CRS) business stream serving the Korean chemical, agrochemical, and pharmaceutical markets.

Prior to joining Harlan CRS, Cho was director of market access and business development for Zuellig Pharma Korea, an $8 billion subsidiary of the Zuellig Group, providing contract services and clinical reach to multinational companies in more than 15 countries. He also held sales, marketing, and management positions during his 14 years with LG Life Sciences and served in the Special Forces of the Korean Army.

Cho earned a bachelor’s degree and Doctor of Veterinary Medicine degree from Seoul National University.

Source: Harlan



blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here